2016
DOI: 10.5350/dajpn2016290410
|View full text |Cite
|
Sign up to set email alerts
|

Capgras syndrome after use of synthetic cannabinoids: an adolescent case

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

2
6
0

Year Published

2018
2018
2024
2024

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 8 publications
(8 citation statements)
references
References 21 publications
2
6
0
Order By: Relevance
“…Capgras syndrome associated with cannabis has been described mainly in male patients between 17 and 30 years old, either after chronic or acute cannabinoid consumption, which is consistent with the information described in this case [ 1 , 9 ].…”
Section: Discussionsupporting
confidence: 90%
See 1 more Smart Citation
“…Capgras syndrome associated with cannabis has been described mainly in male patients between 17 and 30 years old, either after chronic or acute cannabinoid consumption, which is consistent with the information described in this case [ 1 , 9 ].…”
Section: Discussionsupporting
confidence: 90%
“…Capgras syndrome is a part of the delusional misidentification syndromes. In this condition, the patient believes that identical individuals have impersonated the people close to them, leading to aggression or even homicide of their relatives [1][2][3][4]. Capgras syndrome was first described in 1923 by Joseph Capgras and Jean Reboul-Lachaux, who reported the case of a 53-year-old female patient, who assured that her children, husband, and later the local police, doctors, neighbors, and even herself were being replaced by doubles [5].…”
Section: Introductionmentioning
confidence: 99%
“…The full text of remaining 216 papers was searched, and a further 192 papers excluded due to not fulfilling the inclusion criteria (Fig 1). After abstraction and full text screening, a total of 24 articles were selected for review: 2 toxicology reports (Monte et al, 2017;Waugh et al, 2016), 4 casecontrol studies (Altintas et al, 2016;Bassir Nia et al, 2016;Shalit et al, 2016;Welter et al, 2017), 3 cross-sectional analyses (Glue et al, 2013;Manseau et al, 2017;Vallersnes et al, 2016) and 15 case reports (Barcelo et al, 2017;Benford and Caplan, 2011;Coppola and Mondola, 2017;Hurst et al, 2011;Johnson et al, 2011;Mahgoub and Young, 2017;Meijer et al, 2014;Muller et al, 2017;Oliveira et al, 2017;Oluwabusi et al, 2012;Ozer et al, 2016;Roberto et al, 2016;Rojek et al, 2017;Samaan et al, 2016; Van der Veer and Friday, 2011) ( Figure 1).…”
Section: Study Selectionmentioning
confidence: 99%
“…Ozer et al (75) described a case of an adolescent with a new-onset psychosis following inhalation of a mixture of SC called “Bonsai.” Olanzapine (10 mg daily) was prescribed and the subject was followed up 3 months after discharge without a recurrence of psychotic symptoms (75).…”
Section: Resultsmentioning
confidence: 99%
“…From a therapeutic perspective, benzodiazepines are useful for managing anxiety, agitation, and seizure risk, together with a supportive/symptomatic therapy (1, 7, 30, 32, 36, 39, 41, 46, 48, 5961, 71, 79, 81). Olanzapine, clozapine, quetiapine, and aripiprazole represent the main prescribed antipsychotic treatments in SC-induced psychoses (1, 7, 37, 50, 57, 60, 62, 6567, 70, 75, 85, 86), while haloperidol, risperidone, and paliperidone have been prescribed/used in isolated cases (45, 53, 63, 73, 85).…”
Section: Discussionmentioning
confidence: 99%